Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients - PubMed (original) (raw)
Clinical Trial
. 2012 Jul 1;131(1):140-9.
doi: 10.1002/ijc.26365. Epub 2011 Sep 14.
Heinrich Griesemann, Stefan Stevanović, Susan Feyerabend, Reinhild Klein, Sebastian Attig, Jörg Hennenlotter, Dorothee Wernet, Dmitri V Kuprash, Alexei Y Sazykin, Steve Pascolo, Arnulf Stenzl, Cécile Gouttefangeas, Hans-Georg Rammensee
Affiliations
- PMID: 21858810
- DOI: 10.1002/ijc.26365
Clinical Trial
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
Melanie Widenmeyer et al. Int J Cancer. 2012.
Abstract
CD4(+) T cells have been shown to be crucial for the induction and maintenance of cytotoxic T cell responses and to be also capable of mediating direct tumor rejection. Therefore, the anticancer therapeutic efficacy of peptide-based vaccines may be improved by addition of HLA class II epitopes to stimulate T helper cells. Survivin is an apoptosis inhibiting protein frequently overexpressed in tumors. Here we describe the first immunological evaluation of a survivin-derived CD4(+) T cell epitope in a multipeptide immunotherapy trial for prostate carcinoma patients. The survivin peptide is promiscuously presented by several human HLA-DRB1 molecules and, most importantly, is naturally processed by dendritic cells. In vaccinated patients, it was able to induce frequent, robust and multifunctional CD4(+) T cell responses, as monitored by IFN-γ ELISPOT and intracellular cytokine staining. Thus, this HLA-DR restricted epitope is broadly immunogenic and should be valuable for stimulating T helper cells in patients suffering from a wide range of tumors.
Copyright © 2011 UICC.
Similar articles
- Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J, Ohkuri T, Togashi Y, Kitamura H, Okuno K, Nishimura T. Ohtake J, et al. Immunol Lett. 2014 Sep;161(1):20-30. doi: 10.1016/j.imlet.2014.04.010. Epub 2014 Apr 30. Immunol Lett. 2014. PMID: 24794408 Clinical Trial. - Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR. Tomimaru Y, et al. Vaccine. 2015 Mar 3;33(10):1256-66. doi: 10.1016/j.vaccine.2015.01.037. Epub 2015 Jan 25. Vaccine. 2015. PMID: 25629522 Free PMC article. - Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319 - CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M, Kallinteris NL, von Hofe E. Xu M, et al. Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Vaccine. 2012. PMID: 22386748 Review. - Peptide epitope identification for tumor-reactive CD4 T cells.
Kobayashi H, Celis E. Kobayashi H, et al. Curr Opin Immunol. 2008 Apr;20(2):221-7. doi: 10.1016/j.coi.2008.04.011. Epub 2008 May 20. Curr Opin Immunol. 2008. PMID: 18499419 Free PMC article. Review.
Cited by
- DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts.
Goyal A, Bauer J, Hey J, Papageorgiou DN, Stepanova E, Daskalakis M, Scheid J, Dubbelaar M, Klimovich B, Schwarz D, Märklin M, Roerden M, Lin YY, Ma T, Mücke O, Rammensee HG, Lübbert M, Loayza-Puch F, Krijgsveld J, Walz JS, Plass C. Goyal A, et al. Nat Commun. 2023 Oct 23;14(1):6731. doi: 10.1038/s41467-023-42417-w. Nat Commun. 2023. PMID: 37872136 Free PMC article. - Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, Majeti R, Weissman IL, Rammensee HG, Walz JS. Nelde A, et al. Blood Cancer Discov. 2023 Nov 1;4(6):468-489. doi: 10.1158/2643-3230.BCD-23-0020. Blood Cancer Discov. 2023. PMID: 37847741 Free PMC article. - Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines.
Zeng B, Moi D, Tolley L, Molotkov N, Frazer IH, Perry C, Dolcetti R, Mazzieri R, Cruz JLG. Zeng B, et al. Cells. 2023 Aug 18;12(16):2094. doi: 10.3390/cells12162094. Cells. 2023. PMID: 37626903 Free PMC article. - Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications.
Wright S, Burkholz SR, Zelinsky C, Wittman C, Carback RT, Harris PE, Blankenberg T, Herst CV, Rubsamen RM. Wright S, et al. Int J Mol Sci. 2023 Jul 23;24(14):11827. doi: 10.3390/ijms241411827. Int J Mol Sci. 2023. PMID: 37511584 Free PMC article. - Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study.
Burkholz SR, Herst CV, Carback RT, Harris PE, Rubsamen RM. Burkholz SR, et al. Vaccines (Basel). 2023 Mar 13;11(3):644. doi: 10.3390/vaccines11030644. Vaccines (Basel). 2023. PMID: 36992227 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials